Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Moderna’s COVID-19 Vaccine To Move Faster Into Phase III

Three Veterans Recruited To Add Experience To Team

Executive Summary

mRNA company confident as it heads towards Phase II trials, but says efficacy and approval will not be a ‘binary event’.

You may also be interested in...



Pharma Leaders Confront Another Daunting Challenge: Meeting COVID-19 Demand

Pharma leaders at the CNBC Healthy Returns virtual conference said they are optimistic industry will deliver a SARS-COV-2 vaccine, but ramping up the supply will require time and collaboration.

Novartis Nominates Ex-BMS Chief As It Pursues US Growth Strategy

The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.

Corbus And Janux Lead Q1’s Small-Cap Winners

Corbus has presence in both antibody drug conjugates and obesity, and was the stand-out small-cap target for investors with a fivefold increase in its share price in Q1.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC142184

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel